ArticleDiscover oncology2026
PSMA/PET-guided stereotactic radiosurgery treatment for intracranial metastases from prostate cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostate-specific membrane antigen in malignant brain tumors: vascular heterogeneity, imaging promise, and therapeutic challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen-targeted molecular imaging with positron emission tomography (PSMA/PET) is being increasingly incorporated into the clinical care of patients with suspected metastatic or biochemically recurrent prostate cancer, allowing for metastasis-directed therapies. Brain metastases from prostate cancer are rare and portend a poor prognosis. We present a case series of patients with intracranial prostatic brain metastasis detected on PSMA/PET and discuss its application for cranial radiosurgery.
methodsA prospectively collected database was queried for prostate cancer patients who presented with intracranial metastasis based on PSMA/PET from January 2020 to December 2024 in a single institution. The clinical course, imaging findings, and treatments were reviewed.
resultsAmong the prostate cancer patients treated at the Gamma Knife radiosurgery (GKRS) department, ten had undergone PSMA/PET after biochemical recurrence, yielding a new diagnosis of single or multiple intracranial metastases, with brain, calvarial, or dural lesions (mean standardized uptake value of 12.5). Their median age was 64 years. Two patients presented with headaches and two suffered from neurologic changes. The prescribed dose ranged from 12 to 21 Gy in one to three fractions. Brain MRI was acquired for all patients and showed that lesions up to 0.061 cc presented a false negative result. Patients were monitored for a median of 6.5 months with brain MRIs, only two with PSMA/PET. Four patients underwent GKRS in addition to treatment with 177Lu-PSMA, with no evidence of acute radiation toxicity.
conclusionsBrain metastases from prostate cancer are rare and can be effectively treated with GKRS. PSMA/PET combined with MRI allows for improved detection of new or recurrent brain metastases and treatment response evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.